What does FARMAGORA do?

FARMAGORA is a pharmacy in Ternat. Public Limited, started on 7 December 1988, 1 establishment.

What is the address of FARMAGORA?

The registered office of FARMAGORA is located at Marktplein 10, 1740 Ternat.

Is FARMAGORA still active?

Yes. According to the CBE (30 October 2026) FARMAGORA is active, legal situation “Normale toestand”, started on 7 December 1988.

Is FARMAGORA registered on Peppol?

Yes, FARMAGORA is registered on the Peppol network with ID 0208:0436025193.

What is the enterprise number of FARMAGORA?

The enterprise number of FARMAGORA is BE0436025193.

When was FARMAGORA founded?

FARMAGORA was founded on 7 December 1988.

Who are the directors of FARMAGORA?

According to the 2025 annual accounts, the directors of FARMAGORA are: Pharmacura BVBA, Jozef Asselman.

Is FARMAGORA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 7 December 1988; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did FARMAGORA make in 2025?

FARMAGORA posted a profit after taxes of € 3,424 in financial year 2025.

What is the revenue of FARMAGORA?

As a small company, FARMAGORA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 299,877.

How much does an employee at FARMAGORA earn?

The average wage cost per full-time employee at FARMAGORA was € 74,200 in 2025: staff costs of € 230,163 for 3.1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does FARMAGORA have?

According to the 2025 annual accounts, FARMAGORA has 3.1 full-time equivalents (FTE).

FARMAGORA (Public Limited) - Ternat - BE0436025193

Dossier FARMAGORA, printed on 30 October 2026 from databakkes.be/en/0436025193/farmagora. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

FARMAGORA from Ternat, company number BE0436025193, closed financial year 2025 with a result of € 3,424 after tax. For that financial year FARMAGORA recorded a gross margin of € 299,877 and equity of € 1.6 million. Compared with financial year 2024, the result moved from € 3,609 to € 3,424. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 31, 2026.

What it is worth Growing

€ 1.6 million

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 3,424

▼ 5% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 527,010

▲ 6% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 1.5 million.

People and assets in 2025

Full-time equivalents

3.1

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 230,163

▲ 4% vs 2024

€ 74,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 20,652

▼ 28% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 89,779

▼ 4% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 42,063

▲ 16% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 205,335 Gross margin 2022: € 205,335 First fiscal year in the series	€ 231,107 Gross margin 2023: € 231,107 ▲ 13% vs 2022 (€ 205,335) Favourable step	€ 261,893 Gross margin 2024: € 261,893 ▲ 13% vs 2023 (€ 231,107) Favourable step	€ 299,877 Gross margin 2025: € 299,877 ▲ 15% vs 2024 (€ 261,893) Favourable step	▲ 15%
Profit after taxes	€ -5,575 Profit after taxes 2022: € -5,575 First fiscal year in the series	€ -1,058 Profit after taxes 2023: € -1,058 ▲ € 4,516 vs 2022 (€ -5,575) Favourable step	€ 3,609 Profit after taxes 2024: € 3,609 ▲ € 4,667 vs 2023 (€ -1,058) Favourable step	€ 3,424 Profit after taxes 2025: € 3,424 ▼ 5% vs 2024 (€ 3,609) Unfavourable step	▼ 5%
Equity	€ 1,584,551 Equity 2022: € 1,584,551 First fiscal year in the series	€ 1,583,492 Equity 2023: € 1,583,492 Unchanged (€ 1,584,551) Unfavourable step	€ 1,587,101 Equity 2024: € 1,587,101 Unchanged (€ 1,583,492) Favourable step	€ 1,590,526 Equity 2025: € 1,590,526 Unchanged (€ 1,587,101) Favourable step
Total debts	€ 363,965 Total debts 2022: € 363,965 First fiscal year in the series	€ 278,757 Total debts 2023: € 278,757 ▼ 23% vs 2022 (€ 363,965) Favourable step	€ 203,949 Total debts 2024: € 203,949 ▼ 27% vs 2023 (€ 278,757) Favourable step	€ 189,706 Total debts 2025: € 189,706 ▼ 7% vs 2024 (€ 203,949) Favourable step	▼ 7%
Cash	€ 649,410 Cash 2022: € 649,410 First fiscal year in the series	€ 577,223 Cash 2023: € 577,223 ▼ 11% vs 2022 (€ 649,410) Unfavourable step	€ 497,943 Cash 2024: € 497,943 ▼ 14% vs 2023 (€ 577,223) Unfavourable step	€ 527,010 Cash 2025: € 527,010 ▲ 6% vs 2024 (€ 497,943) Favourable step	▲ 6%
Land & buildings	€ 382,226 Land & buildings 2022: € 382,226 First fiscal year in the series	€ 382,226 Land & buildings 2023: € 382,226 Unchanged (€ 382,226) Unchanged	€ 372,216 Land & buildings 2024: € 372,216 ▼ 3% vs 2023 (€ 382,226) Unchanged	€ 327,465 Land & buildings 2025: € 327,465 ▼ 12% vs 2024 (€ 372,216) Unchanged	▼ 12%
Retained profit	€ 1,460,604 Retained profit 2022: € 1,460,604 First fiscal year in the series	€ 1,459,546 Retained profit 2023: € 1,459,546 Unchanged (€ 1,460,604) Unfavourable step	€ 1,463,155 Retained profit 2024: € 1,463,155 Unchanged (€ 1,459,546) Favourable step	€ 1,466,579 Retained profit 2025: € 1,466,579 Unchanged (€ 1,463,155) Favourable step
Bank debt	€ 104,644 Bank debt 2022: € 104,644 First fiscal year in the series	€ 63,171 Bank debt 2023: € 63,171 ▼ 40% vs 2022 (€ 104,644) Favourable step	€ 21,187 Bank debt 2024: € 21,187 ▼ 66% vs 2023 (€ 63,171) Favourable step	€ 0 Bank debt 2025: € 0 ▼ 100% vs 2024 (€ 21,187) Favourable step	▼ 100%
Balance sheet total	€ 1,948,516 Balance sheet total 2022: € 1,948,516 First fiscal year in the series	€ 1,862,249 Balance sheet total 2023: € 1,862,249 ▼ 4% vs 2022 (€ 1,948,516) Unchanged	€ 1,791,050 Balance sheet total 2024: € 1,791,050 ▼ 4% vs 2023 (€ 1,862,249) Unchanged	€ 1,780,232 Balance sheet total 2025: € 1,780,232 ▼ 1% vs 2024 (€ 1,791,050) Unchanged	▼ 1%
Employees (FTE)	3.1 Employees (FTE) 2022: 3.1 First fiscal year in the series	3.1 Employees (FTE) 2023: 3.1 Unchanged (3.1) Unchanged	3.1 Employees (FTE) 2024: 3.1 Unchanged (3.1) Unchanged	3.1 Employees (FTE) 2025: 3.1 Unchanged (3.1) Unchanged

Key figures of FARMAGORA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to FARMAGORA?

What happened at FARMAGORA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 31, 2026 New annual accounts for financial year 2025: profit of € 3,424 (▼ 5% vs 2024). Source: NBB ↗
2018 Pharmacura BVBA became a director. NBB
2018 Jozef Asselman became a director. NBB
Dec 21, 1988 New establishment in Ternat. KBO
Dec 7, 1988 Start of the company according to the CBE. KBO

In short

From € 5,575 loss in 2022 to € 3,424 profit in 2025.

Paid € 11,918 in corporate taxes since 2022.

Best year ever: 2024, with € 3,609 profit.

On average € 96,700 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

PHARMACURA 99.8%

The stake of PHARMACURA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

FARMAGORA

Behind FARMAGORA are Pharmacura BVBA and Jozef Asselman. The shares are held by PHARMACURA (99.8%).

Directors

According to the 2025 annual accounts

Pharmacura BVBA

Managing director · represented by Paul Asselman

since 2018

Jozef Asselman

Managing director

since 2018

Shareholders

PHARMACURA

99.8%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Marktplein 10

1740 Ternat

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

PHARMACURA same network

€ 240,828 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0436.025.193

VAT number

BE 0436.025.193

Registered office

Marktplein 10, 1740 Ternat

Names & denominations

FARMAGORA

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

7 December 1988

Peppol

Active · Active since 2 Feb 2026

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

FARMAGORA

Financials

What happened to FARMAGORA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions